PBS needs to reflect renal benefit of SGLT2 inhibitors: researchers

New modelling shows thousands of lives could be saved through prevention of diabetes-related end-stage kidney disease, they say

The criteria for government funding of SGLT2 inhibitors need to be updated to better reflect their potential to improve renal outcomes in patients with type 2 diabetes, leading Australian researchers say.

The Baker Heart and Diabetes Institute-led team has also called for a shift away from a 'glucose-centric' view of the drugs and for clinicians and regulators to broaden their focus to the potential for renal and cardiovascular benefits.

The call was prompted by new modelling that showed almost